



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Amgen Inc et al.

Serial No.: 09/559,001

Group Art Unit No.: Unknown

Filed: April 21, 2000

Examiner: Unknown

For: Methods and Compositions for the Prevention and Treatment of Anemia

Docket No.: A-460A

0300
#5/2R
10/21/00

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form.

In accordance with 37 CFR 1.98(d), copies of the patents, publications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/178,292, filed October 23, 1998. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120.

Applicants' position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date:

Please send all future correspondence to:

US Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

7/20/00
Date

R. B. Winter
Signature



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Egrie et al.

Serial No.: 09/559,001

Group Art Unit No.: Unknown

Filed: April 21, 2000

Examiner: Unknown

For: Methods and Compositions for the Prevention and
Treatment of Anemia

Docket No.: A-460A

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicant, by the undersigned attorney/agent, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date:

Please send all future correspondence to:

US Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

7/20/00
Date

D. Taylor
Signature